{
    "root": "a78acad9-1758-41b3-943b-f47bffa86909",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tizanidine",
    "value": "20231109",
    "ingredients": [
        {
            "name": "TIZANIDINE HYDROCHLORIDE",
            "code": "B53E3NMY5C"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        }
    ],
    "indications": "Tizanidine Tablets, USP is a central alpha-2-adrenergic agonist indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with Tizanidine Tablets, USP should be reserved for those daily activities and times when relief of spasticity is most important [see Dosage and Administration(2.1)].",
    "contraindications": "• Recommended starting dose: 2 mg; dose can be repeated at 6 to 8 hour intervals, up to a maximum of 3 doses in 24 hours (2.1) • Dosage can be increased by 2 mg to 4 mg per dose, with 1 to 4 days between increases; total daily dose should not exceed 36 mg (2.1) • Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. These differences could result in a change in tolerability and control of symptoms ( 2.1 , 12.3 ) • To discontinue Tizanidine Tablets, USP, decrease dose slowly to minimize the risk of withdrawal and rebound hypertension, tachycardia, and hypertonia ( 2.2 )",
    "warningsAndPrecautions": "Tizanidine Tablets, USP 4 mg are available as; white to off-white, round, flat beveled, uncoated tablets debossed with product code “503” on one side, and quadrisecting score on the other.\n                  NDC: 71335-1016-1: 30 Tablets in a BOTTLE\n                  NDC: 71335-1016-2: 60 Tablets in a BOTTLE\n                  NDC: 71335-1016-3: 90 Tablets in a BOTTLE\n                  NDC: 71335-1016-4: 120 Tablets in a BOTTLE\n                  NDC: 71335-1016-5: 20 Tablets in a BOTTLE\n                  NDC: 71335-1016-6: 45 Tablets in a BOTTLE\n                  NDC: 71335-1016-7: 140 Tablets in a BOTTLE\n                  NDC: 71335-1016-8: 84 Tablets in a BOTTLE\n                  NDC: 71335-1016-9: 28 Tablets in a BOTTLE\n                  NDC: 71335-1016-0: 112 Tablets in a BOTTLE\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions": "Tizanidine Tablets, USP is contraindicated in patientstaking potent inhibitors of CYP1A2, such as fluvoxamine or ciprofloxacin [\n                        see  Drug Interactions (7.1 ,  7.2 )\n                     ]."
}